Clinical trial
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and…
NCT00408226 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00408226 |
|---|---|
| Title | Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer |
| Official title | Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Cancer, Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | MKC-1, pemetrexed |
| Enrollment | 27 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jan 1, 2012 |
| First posted | Dec 6, 2006 |
| Last update posted | Jan 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: